1-May-2026
No headlines found.
Globe Newswire (Tue, 17-Mar 8:28 AM ET)
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Grifols S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol GRFS.
As of May 1, 2026, GRFS stock price declined to $8.23 with 137,770 million shares trading.
GRFS has a beta of 0.99, meaning it tends to be less sensitive to market movements. GRFS has a correlation of 0.22 to the broad based SPY ETF.
GRFS has a market cap of $5.60 billion. This is considered a Mid Cap stock.
In the last 3 years, GRFS traded as high as $12.15 and as low as $5.30.
The top ETF exchange traded funds that GRFS belongs to (by Net Assets): IBB, BINV, KOMP, SPDW, BSMC.
GRFS has underperformed the market in the last year with a price return of +19.7% while the SPY ETF gained +30.4%. GRFS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.0% and -5.9%, respectively, while the SPY returned +4.4% and +1.5%, respectively.
GRFS support price is $8.03 and resistance is $8.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRFS shares will trade within this expected range on the day.
